Clinical trials: Breast Cancer, Breast Neoplasms
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors.
- Conditions
- Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
- Trial name
- NCT04895709
- Testing
- BMS-986340, BMS-936558-01, Docetaxel
- Where
- 47 sites in United States, Australia and 6 more
- Volunteers
- 1,109 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Persistant Organic Pollutants
Persistant Organics Pollutants in Breast Cancer.
Persistant Organics Pollutants (POP) accumulate in the adipose tissue (AT) and could modulate tumor progression as part of the microenvironment.
- Conditions
- Breast Cancer, Persistant Organic Pollutants, Lymph Node Metastases
- Trial name
- METAPOP (NCT03788187)
- Testing
- Blood test sample, Peritumoral adipose tissue sample
- Volunteers
- 80 people
- Sponsor
- European Georges Pompidou Hospital
Breast Cancer, Endocrine Therapy
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
Exploring the Efficacy and Safety of Different Systemic Treatment Regimens after CDK4/6i Progression in the Real World has significant implications. This study is an observational, real-world study.
- Conditions
- Breast Cancer, Endocrine Therapy, CDK4/6 Inhibitors, Subsequent Treatment
- Trial name
- NCT06033287
- Testing
- Different treatment regimens following progression on CDK4/6 inhibitors.
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Hunan Cancer Hospital
Breast Cancer
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
This is a multicenter, open label, non-inferiority, randomized controlled clinical study. The aim of this study is to evaluate the efficacy and safety of a pegylated liposomal doxorubicin + cyclophosphamide followed by docetaxel…
- Trial name
- NCT05159193
- Testing
- pegylated liposomal doxorubicin (PLD), cyclophosphamide (C), trastuzumab (H)
- Where
- China
- Volunteers
- 372 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32
RATIONALE: Learning about the effect of metformin hydrochloride in breast density of women with early-stage breast cancer may help plan treatment.
- Trial name
- NCT01666171
- Testing
- metformin hydrochloride, clinical observation, diagnostic laboratory biomarker analysis
- Volunteers
- 458 people
- Sponsor
- Cancer and Leukemia Group B
Hormonal Therapy, Breast Cancer
Study of Body Composition in Patients Treated by Adjuvant Hormonal Therapy for Breast Cancer (MetaCa2)
This cross-sectional study of pathophysiology will bring additional informations on body composition of patients treated by adjuvant hormonal therapy for breast cancer. This is a complementary study of Metaca study (AU882).
- Trial name
- MetaCa2 (NCT02509871)
- Testing
- Body composition measurement
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Centre Jean Perrin
Breast Cancer
Enhancing Connections: Helping the Mother With Breast Cancer Support Her Child
This is a 6-state randomized controlled trial (RCT) that uses a behavioral intervention to enhance parenting skills for school age children when a mother is recently diagnosed with early stage breast cancer.
- Trial name
- EC R01 (NCT00194571)
- Testing
- Educational counseling intervention
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- University of Washington
Metastatic Breast Cancer
IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma
Open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting in patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of weekly paclitaxel (80…
- Trial name
- NCT00349934
- Testing
- IMP321
- Where
- 3 sites in France
- Volunteers
- 33 people
- Sponsor
- Immutep S.A.S.
Peripheral Neuropathy
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer
Purpose: The purpose of the study is to test a new way of measuring nerve damage in women with breast cancer receiving chemotherapy drug paclitaxel (Taxol).
- Trial name
- NCT02549534
- Testing
- Axon Reflexes, Axon Flares, Self-Reported Signs & Symptoms of CIPN
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Indiana University
Thrombocytopenia
Herombopag Treated T-DM1 Induced Platelet Reduction
This is a single-arm study planned to enroll 56 breast cancer patients who experienced grade 2 or higher thrombocytopenia following prior chemotherapy and achieved normalization (platelet count ≥100 × 109/L and ≥200 × 109/L)…
- Trial name
- NCT07257809
- Testing
- Herombopag Olamine Tablets
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting
The purpose of the study is to investigate the molecular biology of the tumor in relation to treatment response to chemotherapy, in particular paclitaxel compared to the combination paclitaxel and carboplatin.
- Trial name
- NCT02546232
- Testing
- Carboplatin, Paclitaxel
- Where
- Norway
- Volunteers
- 196 people
- Sponsor
- Oslo University Hospital
Ovarian Carcinoma, Fallopian Tube Carcinoma
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer
- Trial name
- NCT06299163
- Testing
- NM32-2668
- Where
- 11 sites in United States
- Volunteers
- 11 people
- Sponsor
- Numab Therapeutics AG
Triple Negative Breast Cancer, Residual Disease
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
This research study involves Niraparib as a possible treatment for triple negative breast cancer.
- Trial name
- UNITY (NCT03945721)
- Testing
- Niraparib, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
TNBC - Triple-Negative Breast Cancer, Breast Cancer
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
Open label, single-arm, prospective therapeutic trial. Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progression, or treatment intolerance.
- Trial name
- NCT07015853
- Testing
- Pembrolizumab, Radiotherapy, Axatilimab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Stephen Shiao
Lymphedema, Breast Cancer Stage II
Study the Usefulness of Bio-impedance Spectroscopy in the Early Assessment of Breast Cancer Related Lymphoedema
The goal of the study is to investigate the use of bio-impedance spectroscopy in the assessment of breast cancer related lymphoedema in patients operated with lumpectomy or mastectomy, axillary lymph node dissection and…
- Conditions
- Lymphedema, Breast Cancer Stage II, Early Disease Onset
- Trial name
- NCT01599039
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Nij Smellinghe Hosptial
Intraabdominal Hypertension, Breast Neoplasms
DIEP Flap Surgery and Intraabdominal Pressure
Aim: The primary aim of this study is to test if closure of the abdominal donor site increases the Intraabdominal Pressure (IAP) in women undergoing secondary Deep Inferior epigastric perforator (DIEP) flap breast reconstruction.
- Trial name
- NCT05764577
- Testing
- DIEP flap surgery
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Aalborg University Hospital
Modified Radical Mastectomy, Breast Cancer
Comparison Between Erector Spinae Plane Block Versus Serratus Anterior Plane Block Regarding Analgesia Post Modified Radical Mastectomy
The goal of this clinical trial is to compare Ultrasound Guided Erector Spinae and Ultrasound Guided Serratus Anterior Plane Block post Modified Radical Mastectomy in adult females.
- Trial name
- FMASUMD66/2025 (NCT06947330)
- Testing
- Unilateral Erector Spinae group, Unilateral Serratus Anterior group
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Kholoud Usama
Breast Neoplasms
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer
The general aim of this study is to investigate the efficacy and safety of afatinib alone and in combination with weekly vinorelbine (in patients who progress on afatinib monotherapy within this trial) as treatment in patients…
- Trial name
- NCT01325428
- Testing
- Afatinib once daily (OD), Vinorelbine Weekly
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 26 people
- Sponsor
- Boehringer Ingelheim
Stage I Breast Cancer, Stage II Breast Cancer
Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer
This clinical trial will enroll up to 130 adult women with a confirmed diagnosis of clinical stage 1 or 2 breast cancer who are undergoing breast cancer surgery with lumpectomy or mastectomy and planned axillary sentinel node…
- Trial name
- NCT02419807
- Testing
- Indocyanine Green Solution, Technetium Tc-99m Sulfur Colloid, Lymphoscintigraphy
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Case Comprehensive Cancer Center
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.